H. Barailler, G. Salomon, and C. Dutriaux, Effets indésirables et conséquences des anti-PD-1 chez les patients très âgés (? 80 ans) traités pour un mélanome métastatique, 2018.

, Ann Dermatol Vénéréologie, vol.145, pp.321-322

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, pp.1627-1639, 2015.

C. Boutros, A. Tarhini, and E. Routier, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat Rev Clin Oncol, vol.13, pp.473-486, 2016.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, pp.373-383, 1987.

R. Elias, T. Karantanos, E. Sira, and K. L. Hartshorn, Immunotherapy comes of age: Immune aging & checkpoint inhibitors, J Geriatr Oncol, vol.8, pp.229-235, 2017.

M. Extermann, Measuring comorbidity in older cancer patients, Eur J Cancer Oxf Engl, vol.36, pp.453-471, 1990.

C. F. Friedman and J. D. Wolchok, Checkpoint inhibition and melanoma: Considerations in treating the older adult, J Geriatr Oncol, vol.8, pp.237-241, 2017.

C. Helissey, C. Vicier, and S. Champiat, The development of immunotherapy in older adults: New treatments, new toxicities?, J Geriatr Oncol, vol.7, pp.325-333, 2016.

F. S. Hodi, S. J. O'day, and D. F. Mcdermott, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med, vol.363, pp.711-723, 2010.

T. Z. Horvat, N. G. Adel, and T. Dang, Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, vol.33, pp.3193-3198, 2015.

V. Hurez, P. Á. Svatek, R. S. Curiel, and T. J. , Considerations for successful cancer immunotherapy in aged hosts: Ageing and cancer immunotherapy, Clin Exp Immunol, vol.187, pp.53-63, 2017.

T. Ibrahim, C. Mateus, M. Baz, and C. Robert, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother, vol.67, pp.1571-1578, 2018.

S. Y. Kim, S. N. Kim, and H. J. Hahn, Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma, J Am Acad Dermatol, vol.72, pp.1036-1046, 2015.

V. Leroy, E. Gerard, and C. Dutriaux, Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol Immunother, 2019.

G. V. Long, J. Schachter, and A. Ribas, 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J Clin Oncol, vol.36, pp.9503-9503, 2018.

J. B. Macdonald, A. C. Dueck, and R. J. Gray, Malignant melanoma in the elderly: different regional disease and poorer prognosis, J Cancer, vol.2, pp.538-543, 2011.

I. Mian, M. Yang, and H. Zhao, Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab, J Clin Oncol, vol.34, pp.3047-3047, 2016.

T. F. Nishijima, H. B. Muss, S. S. Shachar, and S. J. Moschos, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev, vol.45, pp.30-37, 2016.

M. Perier-muzet, E. Gatt, and J. Péron, Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma, JAMA Dermatol, vol.154, p.82, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01847410

M. A. Postow, J. Chesney, and A. C. Pavlick, Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, N Engl J Med, vol.372, pp.2006-2017, 2015.

M. J. Rees, H. Liao, and J. Spillane, Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions, Eur J Surg Oncol EJSO, vol.42, pp.1359-1366, 2016.

A. Ribas, I. Puzanov, and R. Dummer, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, issue.15, pp.83-85, 2015.

C. Robert, G. V. Long, and B. Brady, Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med, vol.372, pp.320-330, 2015.

C. Robert, L. Thomas, and I. Bondarenko, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N Engl J Med, vol.364, pp.2517-2526, 2011.

J. Schachter, A. Ribas, and G. V. Long, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label BMS: consultant, Pham-Ledard) dépenses de déplacement congrès, 2017.

, MSD: consultant (Beylot-Barry, Dutriaux), honoraires d'orateur (Beylot-Barry, Dutriaux, Pham-Ledard) dépenses de déplacement congrès

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med, vol.372, pp.320-350, 2015.

J. Schachter, A. Ribas, G. V. Long, A. Arance, J. Grob et al., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-62, 2017.

G. V. Long, J. Schachter, A. Ribas, A. M. Arance, J. Grob et al., 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J Clin Oncol, vol.36, p.9503, 2018.

J. D. Wolchok, V. Chiarion-sileni, R. Gonzalez, P. Rutkowski, J. Grob et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med, vol.377, pp.1345-56, 2017.

V. Leroy, E. Gerard, C. Dutriaux, S. Prey, A. Gey et al., Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol Immunother, 2019.

C. Sileni, V. Pigozzo, J. Ascierto, P. A. Grimaldi, A. M. Maio et al., Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J Exp Clin Cancer Res, vol.33, 2014.

M. Freeman and J. Weber, Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J Immunother Cancer, vol.3, 2015.

A. S. Betof, R. D. Nipp, A. Giobbie-hurder, R. Johnpulle, K. Rubin et al., Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-71, 2017.

L. Repetto, D. Comandini, and S. Mammoliti, Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients, Crit Rev Oncol Hematol, vol.37, pp.147-52, 2001.

A. Vigano, N. Donaldson, I. J. Higginson, E. Bruera, S. Mahmud et al., Quality of life and survival prediction in terminal cancer patients: A multicenter study, Cancer, vol.101, pp.1090-1098, 2004.

V. E. Von-gruenigen, H. Q. Huang, K. M. Gil, H. E. Frasure, D. K. Armstrong et al., The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group Study, Gynecol Oncol, vol.124, pp.379-82, 2012.

M. Epplein, Y. Zheng, W. Zheng, Z. Chen, K. Gu et al., Quality of Life After Breast Cancer Diagnosis and Survival, J Clin Oncol, vol.29, pp.406-418, 2011.

M. O. Carrere, V. Buthion, and P. Castel, Modalités de recours au dispositifs gériatriques lors de la prise en charge des personnes atteintes de cancer. Spécificité de la prise en charge des patients âgés atteints de cancer. Lyon: Groupe de Recherche Economie de la Santé et Réseaux de soins en Cancérologie, 2006.

H. Wildiers, M. Mauer, A. Pallis, A. Hurria, S. G. Mohile et al., End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, pp.3711-3719, 2013.

K. A. Malkhasyan, Y. Zakharia, and M. Milhem, Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-531, 2017.

G. Quereux, M. Bourdon, M. Blanchin, P. Tessier, M. Campone et al., Évolution de la qualité de vie au cours du temps suite à un diagnostic d'un mélanome ou d'un cancer du sein : résultats comparatifs sur deux ans, Ann Dermatol Vénéréologie, vol.144, p.311, 2017.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, pp.373-83, 1987.

M. A. Sprangers, A. Cull, K. Bjordal, M. Groenvold, and N. K. Aaronson, Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life, Qual Life Res Int J Qual Life Asp Treat Care Rehabil, vol.2, pp.287-95, 1993.

P. V. Chernyshov, A. Lallas, L. Tomas-aragones, M. Arenbergerova, M. Samimi et al., Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer, J Eur Acad Dermatol Venereol, 2019.

S. Wheelwright, A. Darlington, D. Fitzsimmons, P. Fayers, J. I. Arraras et al., International validation of the EORTC QLQ-ELD14 questionnaire for assessment of healthrelated quality of life elderly patients with cancer, Br J Cancer, vol.109, pp.852-860, 2013.

P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Curé et al., Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014.

D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol Off J Am Soc Clin Oncol, vol.16, pp.139-183, 1998.

S. Y. Zafar, S. C. Alexander, K. P. Weinfurt, K. A. Schulman, and A. P. Abernethy, Decision making and quality of life in the treatment of cancer: a review, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.17, pp.117-144, 2009.

Y. Brandberg, H. Johansson, S. Aamdal, L. Bastholt, M. Hernberg et al., Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma, Acta Oncol Stockh Swed, vol.52, pp.1086-93, 2013.

P. N. Butow, A. S. Coates, and S. M. Dunn, Psychosocial predictors of survival in metastatic melanoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, pp.2256-63, 1999.

A. Coates, D. Thomson, G. R. Mcleod, P. Hersey, P. G. Gill et al., Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma, Eur J Cancer Oxf Engl, vol.29, pp.1731-1735, 19901993.

E. T. Hall, S. Singhal, J. Dickerson, B. Gabster, H. Wong et al., Patient reported outcomes for cancer patients receiving immunotherapy: opportunities for palliative care -A Systematic Review, J Pain Symptom Manage, 2019.

D. Cornish, C. Holterhues, L. V. Van-de-poll-franse, J. W. Coebergh, and T. Nijsten, A systematic review of health-related quality of life in cutaneous melanoma, Ann Oncol Off J Eur Soc Med Oncol, vol.20, issue.6, pp.51-58, 2009.

J. Hamel, M. Pe, C. Coens, F. Martinelli, A. Eggermont et al., A systematic review examining factors influencing health related quality of life among melanoma cancer survivors, Eur J Cancer, vol.69, pp.189-98, 2016.

L. Balducci, Management of Cancer in the Older Person: A Practical Approach, The Oncologist, vol.5, pp.224-261, 2000.

K. Cheng and Y. Lim, Quality of life of elderly patients receiving cancer therapy: A systematic review, J Geriatr Oncol, vol.5, p.74, 2014.

T. Ibrahim, C. Mateus, M. Baz, and C. Robert, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol Immunother, vol.67, pp.1571-1579, 2018.

H. Barailler, G. Salomon, C. Dutriaux, S. Prey, E. Gérard et al., Effets indésirables et conséquences des anti-PD-1 chez les patients très âgés (? 80 ans) traités pour un mélanome métastatique, Ann Dermatol Vénéréologie, vol.145, pp.321-323, 2018.

, BIBLIOGRAPHIE 1. Les cancers en France, 2017.

F. Binder-foucard, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

A. Jemal, CA. Cancer J. Clin, vol.58, pp.71-96, 2008.

A. Du-thanh, C. Lesage, E. Ferreira, O. Dereure, and B. Guillot, Place des traitements innovants du mélanome métastatique chez le sujet âgé, Ann. Dermatol. Vénéréologie, vol.142, pp.549-556, 2015.

E. Bastiaannet, Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper, J. Geriatr. Oncol, 2018.

P. F. Austin, Age as a prognostic factor in the malignant melanoma population, Ann. Surg. Oncol, vol.1, pp.487-494, 1994.

D. Ciocan, Distinctive features of melanoma and its management in elderly patients: a population-based study in France, JAMA Dermatol, vol.149, pp.1150-1157, 2013.

B. P. Hazen, A. C. Bhatia, T. Zaim, and R. T. Brodell, The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity, Dermatol. Online J, vol.5, p.3, 1999.

M. E. Vestergaard, P. Macaskill, P. E. Holt, and S. W. Menzies, Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, Br. J. Dermatol, vol.159, pp.669-676, 2008.

N. G. Maher, Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy, J. Eur. Acad. Dermatol. Venereol. JEADV, vol.31, pp.2016-2024, 2017.

V. J. Mcgovern, The classification of malignant melanoma and its histologic reporting, Cancer, vol.32, pp.1446-1457, 1973.

M. Rastrelli, S. Tropea, C. R. Rossi, and M. Alaibac, Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification, Vivo Athens Greece, vol.28, pp.1005-1011, 2014.

A. J. Chamberlain, L. Fritschi, G. G. Giles, J. P. Dowling, and J. W. Kelly, Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch. Dermatol, vol.138, pp.609-614, 2002.

J. S. Goydos and S. L. Shoen, Acral Lentiginous Melanoma. Cancer Treat. Res, vol.167, pp.321-329, 2016.

H. W. Higgins, K. C. Lee, A. Galan, and D. J. Leffell, Melanoma in situ: Part I. Epidemiology, screening, and clinical features, J. Am. Acad. Dermatol, vol.73, pp.191-192, 2015.

J. D. Tacastacas, Update on primary mucosal melanoma, J. Am. Acad. Dermatol, vol.71, pp.366-375, 2014.

L. L. Chen, N. Jaimes, C. A. Barker, K. J. Busam, and A. A. Marghoob, Desmoplastic melanoma: a review, J. Am. Acad. Dermatol, vol.68, pp.825-833, 2013.

D. E. Jaroszewski, B. A. Pockaj, D. J. Dicaudo, and U. Bite, The clinical behavior of desmoplastic melanoma, Am. J. Surg, vol.182, pp.590-595, 2001.

J. E. Gershenwald, Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA, Cancer J. Clin, vol.67, pp.472-492, 2017.

B. Guillot, Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie, Ann. Dermatol. Vénéréologie, vol.145, pp.413-422, 2018.

N. J. Karandikar, C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone, CTLA-4: a negative regulator of autoimmune disease, J. Exp. Med, vol.184, pp.783-788, 1996.

T. L. Walunas, C. Y. Bakker, and J. A. Bluestone, CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med, vol.183, pp.2541-2550, 1996.

G. Q. Phan, Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci, vol.100, pp.8372-8377, 2003.

E. Ileana, S. Champiat, and J. Soria, Immune-Checkpoints: the new anti-cancer immunotherapies, Bull. Cancer, pp.601-610, 2013.

C. Robert, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N. Engl. J. Med, vol.364, pp.2517-2526, 2011.

F. S. Hodi, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med, vol.363, pp.711-723, 2010.

D. Schadendorf, Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, J. Clin. Oncol, vol.33, pp.1889-1894, 2015.

V. A. Trinh and W. Hwu, Ipilimumab in the treatment of melanoma, Expert Opin. Biol. Ther, vol.12, pp.773-782, 2012.

R. C. Liu, G. Consuegra, and P. Fernández-peñas, Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Manag, vol.4, pp.187-202, 2017.

E. Dika, Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study, Eur. J. Dermatol. EJD, vol.27, pp.266-270, 2017.

K. E. Beck, Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte-associated antigen 4, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2283-2289, 2006.

K. C. Kähler and A. Hauschild, Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma, J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG, vol.9, pp.277-286, 2011.

M. Sznol, Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat. Rev, vol.58, pp.70-76, 2017.

Y. Tian, H. Abu-sbeih, and Y. Wang, Immune Checkpoint Inhibitors-Induced Hepatitis, Adv. Exp. Med. Biol, vol.995, pp.159-164, 2018.

, Haute autorité de santé. Comission de la transparence, 2017.

E. I. Buchbinder and A. Desai, CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, Am. J. Clin. Oncol, vol.39, pp.98-106, 2016.

D. F. Mcdermott and M. B. Atkins, PD-1 as a potential target in cancer therapy, Cancer Med, vol.2, pp.662-673, 2013.

R. M. Wong, Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, Int. Immunol, vol.19, pp.1223-1234, 2007.

C. Blank, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, vol.64, pp.1140-1145, 2004.

, ECancer. La situation du cancer en France, 2010.

C. Robert, Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015.

C. Robert, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015.

J. Schachter, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-1862, 2017.

J. D. Wolchok, Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.377, pp.1345-1356, 2017.

G. V. Long, 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J. Clin. Oncol, vol.36, pp.9503-9503, 2018.

G. V. Long, Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials, JAMA Oncol, vol.3, pp.1511-1519, 2017.

X. Zhao, Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, 2002.

T. Freshwater, Evaluation of dosing strategy for pembrolizumab for oncology indications, J. Immunother. Cancer, vol.5, 2017.

C. Robert, Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, J. Clin. Oncol, vol.34, pp.9503-9503, 2016.

C. Robert, Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment, J. Clin. Oncol, vol.35, pp.9504-9504, 2017.

Y. Jansen, Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression, J. Clin. Oncol, vol.35, pp.9539-9539, 2017.

R. Aitmehdi, Arrêt des anti-PD1 dans le mélanome métastatique en réponse complète

, Ann. Dermatol. Vénéréologie, vol.144, pp.89-90, 2017.

R. Ladwa and V. Atkinson, The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma, Melanoma Res, vol.27, pp.168-170, 2017.

Y. J. Jansen, Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma, Ann. Oncol, 2019.

T. F. Nishijima, S. S. Shachar, K. A. Nyrop, and H. B. Muss, Safety and Tolerability of PD

, L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis, vol.22, pp.470-479, 2017.

A. Ribas, Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, pp.908-918, 2015.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N. Engl. J. Med, vol.378, pp.158-168, 2018.

J. Naidoo, Pneumonitis in Patients Treated With Anti-Programmed Death

, Programmed Death Ligand 1 Therapy, J. Clin. Oncol, vol.35, pp.709-717, 2017.

L. K. Collins, M. S. Chapman, J. B. Carter, and F. H. Samie, Cutaneous adverse effects of the immune checkpoint inhibitors, Curr. Probl. Cancer, vol.41, pp.125-128, 2017.

J. Naidoo, Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1, Cancer Immunol. Res, vol.4, pp.383-389, 2016.

J. C. Kao, Neurological Complications Associated With Anti-Programmed Death, vol.1

A. , , vol.74, pp.1216-1222, 2017.

H. Montaudié, J. Pradelli, T. Passeron, J. Lacour, and S. Leroy, Sarcoïdose pulmonaire induite par le nivolumab, Ann. Dermatol. Vénéréologie, vol.143, pp.359-360, 2016.

T. K. Eigentler, Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat. Rev, vol.45, pp.7-18, 2016.

S. Champiat, Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann. Oncol, vol.27, pp.559-574, 2016.

M. Delaunay, Toxicité des inhibiteurs de points de contrôle immunitaires, Rev. Mal. Respir, vol.35, pp.1028-1038, 2018.

I. Puzanov, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunother. Cancer, vol.5, p.95, 2017.

J. B. Haanen, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.28, pp.119-142, 2017.

H. Davies, Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002.

G. V. Long, Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.667-673, 2018.

J. Charles, Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, pp.671-681, 2014.

P. B. Chapman, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011.

P. A. Ascierto, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, vol.17, pp.1248-1260, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01407426

A. Hauschild, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, Lancet Lond. Engl, vol.380, pp.358-365, 2012.

G. V. Long, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, pp.1631-1639, 2017.

C. Robert, Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N. Engl. J. Med, 2019.

R. Dummer, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.19, pp.603-615, 2018.

R. Addeo, S. Zappavigna, A. Luce, S. Facchini, and M. Caraglia, Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC, Expert Opin. Drug Saf, vol.12, pp.729-740, 2013.

P. O. Lang, S. Govind, and R. Aspinall, NPG Neurol. -Psychiatr. -Gériatrie, vol.12, pp.171-181, 2012.

G. Berrut, L. Decker, C. Sunderkötter, H. Kalden, and T. A. Luger, Aging and the skin immune system, Gériatrie Psychol. Neuropsychiatr. Viellissement, vol.7, pp.1256-1262, 1997.

E. Zuelgaray, Caractérisation phénotypique des lymphocytes T résidents de la peau sénescente, Ann. Dermatol. Vénéréologie, vol.145, p.306, 2018.

G. Colonna-romano, Cell Immunosenescence in the Elderly and in Centenarians

, Rejuvenation Res, vol.11, pp.433-439, 2008.

A. Waterstrat and G. Van-zant, Effects of aging on hematopoietic stem and progenitor cells, Curr. Opin. Immunol, vol.21, pp.408-413, 2009.

A. Gruver, L. Hudson, and G. Sempowski, Immunosenescence of ageing, J. Pathol, vol.211, pp.144-156, 2007.

D. B. Palmer, The Effect of Age on Thymic Function, Front. Immunol, vol.4, 2013.

V. Appay, D. Sauce, and M. Prelog, The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals, Aging, vol.2, pp.78-81, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02455362

C. F. Fortin, P. P. Mcdonald, O. Lesur, and T. Fülöp, Aging and Neutrophils: There Is Still Much To Do, Rejuvenation Res, vol.11, pp.873-882, 2008.

A. Panda, Human innate immunosenescence: causes and consequences for immunity in old age, Trends Immunol, vol.30, pp.325-333, 2009.

C. F. Fortin, A. Larbi, G. Dupuis, O. Lesur, and T. Fülöp, GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals, Biogerontology, vol.8, pp.173-187, 2007.

Y. Jing, Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood, Hum. Immunol, vol.70, pp.777-784, 2009.

A. Panda, Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J. Immunol. Baltim. Md, vol.184, pp.2518-2527, 1950.

H. Bruunsgaard, K. Andersen-ranberg, B. Hjelmborg, B. K. Pedersen, and B. Jeune, Elevated levels of tumor necrosis factor alpha and mortality in centenarians, Am. J. Med, vol.115, pp.278-283, 2003.

L. Haynes and S. L. Swain, Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects, Semin. Immunol, vol.24, pp.350-355, 2012.

H. Tsukamoto, Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.18333-18338, 2009.

R. Gregg, The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age, Clin. Exp. Immunol, vol.140, pp.540-546, 2005.

J. E. Nagel, Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors, J. Clin. Invest, vol.81, pp.1096-1102, 1988.

L. Haynes and A. C. Maue, Effects of aging on T cell function, Curr. Opin. Immunol, vol.21, pp.414-417, 2009.

S. Ponnappan and U. Ponnappan, Aging and immune function: molecular mechanisms to interventions, Antioxid. Redox Signal, vol.14, pp.1551-1585, 2011.

J. Dwilewicz-trojaczek, Chronic lymphatic leukemia from B CD5+ cells: characteristics, clinical and laboratory features, and immunophenotyping

, Pol. Tyg. Lek. Wars. Pol, vol.50, pp.12-14, 1960.

Y. Lin, Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors, Immun. Ageing A, vol.13, p.24, 2016.

H. Li, W. Liu, and J. Xie, Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis, Arch. Gerontol. Geriatr, vol.73, pp.257-262, 2017.

E. T. Roberts, M. N. Haan, J. B. Dowd, and A. E. Aiello, Cytomegalovirus Antibody Levels, Inflammation, and Mortality Among Elderly Latinos Over 9 Years of Follow-up, Am. J. Epidemiol, vol.172, pp.363-371, 2010.

A. M. Simanek, Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States, PloS One, vol.6, p.16103, 2011.

H. W. Virgin, E. J. Wherry, and R. Ahmed, Redefining Chronic Viral Infection, Cell, vol.138, pp.30-50, 2009.

S. R. Hadrup, Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly, J. Immunol. Baltim. Md, vol.176, pp.2645-2653, 1950.

C. M. Weyand, J. C. Brandes, D. Schmidt, J. W. Fulbright, and J. J. Goronzy, Functional properties of CD4+ CD28-T cells in the aging immune system, Mech. Ageing Dev, vol.102, pp.131-147, 1998.

M. G. Dorrington and D. M. Bowdish, Immunosenescence and novel vaccination strategies for the elderly, Front. Immunol, vol.4, p.171, 2013.

A. Daste, Immune checkpoint inhibitors and elderly people: A review, Eur. J. Cancer, vol.82, pp.155-166, 2017.

Y. Youm, Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging, Cell Metab, vol.18, pp.519-532, 2013.

C. Falci, Immune senescence and cancer in elderly patients: results from an exploratory study, Exp. Gerontol, vol.48, pp.1436-1442, 2013.

A. Grolleau-julius, E. K. Harning, L. M. Abernathy, and R. L. Yung, Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity, Cancer Res, vol.68, pp.6341-6349, 2008.

C. Matheï, B. Vaes, P. Wallemacq, and J. Degryse, Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort, J. Am. Geriatr. Soc, vol.59, pp.2201-2208, 2011.

G. Pawelec, Does patient age influence anti-cancer immunity?, Semin. Immunopathol, 2018.

A. Martens, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01409624

K. Poropatich, J. Fontanarosa, S. Samant, J. A. Sosman, and B. Zhang, Cancer Immunotherapies: Are They as Effective in the Elderly?, Drugs Aging, vol.34, pp.567-581, 2017.

G. Pawelec, Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?, Clin. Cancer Res, vol.24, pp.5193-5194, 2018.

C. H. Kugel, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.5347-5356, 2018.

Z. Vadasz, T. Haj, A. Kessel, and E. Toubi, Age-related autoimmunity, BMC Med, vol.11, 2013.

J. H. Lewis, Participation of patients 65 years of age or older in cancer clinical trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.21, pp.1383-1389, 2003.

A. S. Betof, Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-971, 2017.

C. Sileni and V. , Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J. Exp. Clin. Cancer Res, vol.33, 2014.

V. Leroy, Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol. Immunother, 2019.

M. Freeman and J. Weber, Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J. Immunother. Cancer, vol.3, 2015.

R. Rai, Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann. Oncol, vol.27, 2016.

T. Ibrahim, C. Mateus, M. Baz, and C. Robert, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol. Immunother, vol.67, pp.1571-1578, 2018.

G. Ben-betzalel, Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients, Eur. J. Cancer, vol.108, pp.61-68, 2019.

R. L. Maher, J. Hanlon, and E. R. Hajjar, Clinical consequences of polypharmacy in elderly, Expert Opin. Drug Saf, vol.13, pp.57-65, 2014.

C. Helissey, C. Vicier, and S. Champiat, The development of immunotherapy in older adults: New treatments, new toxicities?, J. Geriatr. Oncol, vol.7, pp.325-333, 2016.

M. N. Bouchlaka and W. J. Murphy, Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models, Oncoimmunology, vol.2, p.27186, 2013.

S. Bhandari, A. S. Gill, C. A. Perez, and D. Jain, Management of immunotherapy toxicities in older adults, Semin. Oncol, vol.45, pp.226-231, 2018.

W. S. Kendal, Dying with cancer: The influence of age, comorbidity, and cancer site, Cancer, vol.112, pp.1354-1362, 2008.

C. F. Friedman and J. D. Wolchok, Checkpoint inhibition and melanoma: Considerations in treating the older adult, J. Geriatr. Oncol, vol.8, pp.237-241, 2017.

A. N. Dubovsky, S. Arvikar, T. A. Stern, and L. Axelrod, The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited, Psychosomatics, vol.53, pp.103-115, 2012.

J. R. Brahmer, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.1714-1768, 2018.

L. Fardet, I. Petersen, and I. Nazareth, Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study, PLOS Med, vol.13, p.1002024, 2016.

, Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.153-159, 1993.

K. A. Malkhasyan, Y. Zakharia, and M. Milhem, Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-520, 2017.

M. A. Sprangers, A. Cull, K. Bjordal, M. Groenvold, and N. K. Aaronson, The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules, EORTC Study Group on Quality of Life. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.287-295, 1993.

N. K. Aaronson, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993.

J. S. Weber, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015.

D. Schadendorf, Health-related quality of life results from the phase III CheckMate 067 study, Eur. J. Cancer, vol.82, pp.80-91, 2017.

L. Balducci and M. Extermann, Management of cancer in the older person: a practical approach, The Oncologist, vol.5, pp.224-237, 2000.

P. Soubeyran, Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014.

C. Martinez-tapia, Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer, Eur. J. Cancer, vol.83, pp.211-219, 2017.

R. Mccorkle, A specialized home care intervention improves survival among older postsurgical cancer patients, J. Am. Geriatr. Soc, vol.48, pp.1707-1713, 2000.

M. Extermann, A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit. Rev. Oncol. Hematol, vol.49, pp.69-75, 2004.

V. Girre, Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?, J. Gerontol. A. Biol. Sci. Med. Sci, vol.63, pp.724-730, 2008.

P. Caillet, Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J. Clin. Oncol, vol.29, pp.3636-3642, 2011.

S. Novello, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.27, pp.1-27, 2016.

F. Grossi, Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme, Eur. J. Cancer, vol.100, pp.126-134, 2018.

Y. Wu, Q. Ju, B. Qian, F. Zhang, and H. Shi, The effectiveness of PD-1 inhibitors in nonsmall cell lung cancer (NSCLC) patients of different ages, Oncotarget, vol.9, 2018.

R. Elias, J. Morales, and C. Presley, Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults, Curr. Oncol. Rep, vol.19, 2017.

N. Malats and F. X. Real, Epidemiology of bladder cancer, Hematol. Oncol. Clin. North Am, vol.29, pp.177-189, 2015.

C. Kandoth, Mutational landscape and significance across 12 major cancer types, Nature, vol.502, pp.333-339, 2013.

D. Stenehjem, D. Tran, M. Nkrumah, and S. Gupta, PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer, OncoTargets Ther, vol.11, pp.5973-5989, 2018.

J. Bellmunt, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017.

M. D. Galsky, A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy, Lancet Oncol, vol.12, pp.211-214, 2011.

A. V. Balar, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, singlearm, phase 2 study, Lancet Oncol, vol.18, pp.1483-1492, 2017.

P. Sharma, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-322, 2017.

A. M. Menzies, Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Ann. Oncol, vol.443, 2016.

A. Ackerman, Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors: Sequencing of Melanoma Therapies, Cancer, vol.120, pp.1695-1701, 2014.

M. Amini-adle, Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma, BMC Cancer, vol.18, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01911405

Q. Ma, Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data, BMC Cancer, vol.18, 2018.

J. L. Mcquade, Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis, Lancet Oncol, vol.19, pp.310-322, 2018.

M. B. Atkins and J. Larkin, Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives, JNCI J. Natl. Cancer Inst, vol.108, 2016.

M. S. Pelster and R. N. Amaria, Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials, Ther. Adv. Med. Oncol, vol.11, p.175883591983082, 2019.

B. Pulluri, A. Kumar, M. Shaheen, J. Jeter, and S. Sundararajan, Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance, Pharmacol. Res, vol.123, pp.95-102, 2017.

A. Ribas, F. S. Hodi, M. Callahan, C. Konto, and J. Wolchok, Hepatotoxicity with Combination of Vemurafenib and Ipilimumab, N. Engl. J. Med, vol.368, pp.1365-1366, 2013.

A. Ribas, Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J. Clin. Oncol, vol.33, pp.3003-3003, 2015.

R. J. Sullivan, Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity, J. Clin. Oncol, vol.35, pp.3063-3063, 2017.

P. A. Ascierto, 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma, Ann. Oncol, vol.29, 2018.

H. A. Tawbi and -. , Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM), J. Clin. Oncol, vol.36, pp.9560-9560, 2018.

R. Dummer, Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma, J. Clin. Oncol, vol.36, pp.189-189, 2018.

P. A. Ascierto, Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program, Cancer Invest, vol.32, pp.144-149, 2014.

H. A. Tawbi, Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, N. Engl. J. Med, vol.379, pp.722-730, 2018.

G. V. Long, Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort, J. Clin. Oncol, vol.34, pp.9506-9506, 2016.

D. Schadendorf, Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.3807-3814, 2017.

M. H. Pollack, Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma, Ann. Oncol, vol.29, pp.250-255, 2018.

J. Fernandes, Hospitalisation costs of metastatic melanoma in France; the MELISSA study, MELanoma In hoSpital coSts Assessment). BMC Health Serv. Res, vol.17, 2017.

S. R. Ghate, Z. Li, J. Tang, and A. R. Nakasato, Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly, Am. Health Drug Benefits, vol.11, pp.334-343, 2018.

F. Binder-foucard, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

A. Jemal, CA. Cancer J. Clin, vol.58, pp.71-96, 2008.

A. Du-thanh, C. Lesage, E. Ferreira, O. Dereure, and B. Guillot, Place des traitements innovants du mélanome métastatique chez le sujet âgé, Ann. Dermatol. Vénéréologie, vol.142, pp.549-556, 2015.

E. Bastiaannet, Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper, J. Geriatr. Oncol, 2018.

P. F. Austin, Age as a prognostic factor in the malignant melanoma population, Ann. Surg. Oncol, vol.1, pp.487-494, 1994.

D. Ciocan, Distinctive features of melanoma and its management in elderly patients: a population-based study in France, JAMA Dermatol, vol.149, pp.1150-1157, 2013.

B. P. Hazen, A. C. Bhatia, T. Zaim, and R. T. Brodell, The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity, Dermatol. Online J, vol.5, p.3, 1999.

M. E. Vestergaard, P. Macaskill, P. E. Holt, and S. W. Menzies, Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting, Br. J. Dermatol, vol.159, pp.669-676, 2008.

N. G. Maher, Detection of desmoplastic melanoma with dermoscopy and reflectance confocal microscopy, J. Eur. Acad. Dermatol. Venereol. JEADV, vol.31, pp.2016-2024, 2017.

V. J. Mcgovern, The classification of malignant melanoma and its histologic reporting, Cancer, vol.32, pp.1446-1457, 1973.

M. Rastrelli, S. Tropea, C. R. Rossi, and M. Alaibac, Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification, Vivo Athens Greece, vol.28, pp.1005-1011, 2014.

A. J. Chamberlain, L. Fritschi, G. G. Giles, J. P. Dowling, and J. W. Kelly, Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch. Dermatol, vol.138, pp.609-614, 2002.

J. S. Goydos and S. L. Shoen, Acral Lentiginous Melanoma. Cancer Treat. Res, vol.167, pp.321-329, 2016.

H. W. Higgins, K. C. Lee, A. Galan, and D. J. Leffell, Melanoma in situ: Part I. Epidemiology, screening, and clinical features, J. Am. Acad. Dermatol, vol.73, pp.191-192, 2015.

J. D. Tacastacas, Update on primary mucosal melanoma, J. Am. Acad. Dermatol, vol.71, pp.366-375, 2014.

L. L. Chen, N. Jaimes, C. A. Barker, K. J. Busam, and A. A. Marghoob, Desmoplastic melanoma: a review, J. Am. Acad. Dermatol, vol.68, pp.825-833, 2013.

D. E. Jaroszewski, B. A. Pockaj, D. J. Dicaudo, and U. Bite, The clinical behavior of desmoplastic melanoma, Am. J. Surg, vol.182, pp.590-595, 2001.

J. E. Gershenwald, Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA, Cancer J. Clin, vol.67, pp.472-492, 2017.

B. Guillot, Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie, Ann. Dermatol. Vénéréologie, vol.145, pp.413-422, 2018.

N. J. Karandikar, C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone, CTLA-4: a negative regulator of autoimmune disease, J. Exp. Med, vol.184, pp.783-788, 1996.

T. L. Walunas, C. Y. Bakker, and J. A. Bluestone, CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med, vol.183, pp.2541-2550, 1996.

G. Q. Phan, Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma, Proc. Natl. Acad. Sci, vol.100, pp.8372-8377, 2003.

E. Ileana, S. Champiat, and J. Soria, Immune-Checkpoints: the new anti-cancer immunotherapies, Bull. Cancer, pp.601-610, 2013.

C. Robert, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, N. Engl. J. Med, vol.364, pp.2517-2526, 2011.

F. S. Hodi, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med, vol.363, pp.711-723, 2010.

D. Schadendorf, Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, J. Clin. Oncol, vol.33, pp.1889-1894, 2015.

V. A. Trinh and W. Hwu, Ipilimumab in the treatment of melanoma, Expert Opin. Biol. Ther, vol.12, pp.773-782, 2012.

R. C. Liu, G. Consuegra, and P. Fernández-peñas, Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Manag, vol.4, pp.187-202, 2017.

E. Dika, Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study, Eur. J. Dermatol. EJD, vol.27, pp.266-270, 2017.

K. E. Beck, Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte-associated antigen 4, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2283-2289, 2006.

K. C. Kähler and A. Hauschild, Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma, J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG, vol.9, pp.277-286, 2011.

M. Sznol, Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management, Cancer Treat. Rev, vol.58, pp.70-76, 2017.

Y. Tian, H. Abu-sbeih, and Y. Wang, Immune Checkpoint Inhibitors-Induced Hepatitis, Adv. Exp. Med. Biol, vol.995, pp.159-164, 2018.

, Haute autorité de santé. Comission de la transparence, 2017.

E. I. Buchbinder and A. Desai, CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition, Am. J. Clin. Oncol, vol.39, pp.98-106, 2016.

D. F. Mcdermott and M. B. Atkins, PD-1 as a potential target in cancer therapy, Cancer Med, vol.2, pp.662-673, 2013.

R. M. Wong, Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs, Int. Immunol, vol.19, pp.1223-1234, 2007.

C. Blank, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res, vol.64, pp.1140-1145, 2004.

, ECancer. La situation du cancer en France, 2010.

C. Robert, Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N. Engl. J. Med, vol.372, pp.320-330, 2015.

C. Robert, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015.

J. Schachter, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, pp.1853-1862, 2017.

J. D. Wolchok, Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.377, pp.1345-1356, 2017.

G. V. Long, 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006, J. Clin. Oncol, vol.36, pp.9503-9503, 2018.

G. V. Long, Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials, JAMA Oncol, vol.3, pp.1511-1519, 2017.

X. Zhao, Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, 2002.

T. Freshwater, Evaluation of dosing strategy for pembrolizumab for oncology indications, J. Immunother. Cancer, vol.5, 2017.

C. Robert, Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, J. Clin. Oncol, vol.34, pp.9503-9503, 2016.

C. Robert, Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment, J. Clin. Oncol, vol.35, pp.9504-9504, 2017.

Y. Jansen, Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression, J. Clin. Oncol, vol.35, pp.9539-9539, 2017.

R. Aitmehdi, Arrêt des anti-PD1 dans le mélanome métastatique en réponse complète

, Ann. Dermatol. Vénéréologie, vol.144, pp.89-90, 2017.

R. Ladwa and V. Atkinson, The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma, Melanoma Res, vol.27, pp.168-170, 2017.

Y. J. Jansen, Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma, Ann. Oncol, 2019.

T. F. Nishijima, S. S. Shachar, K. A. Nyrop, and H. B. Muss, Safety and Tolerability of PD

, L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis, vol.22, pp.470-479, 2017.

A. Ribas, Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, vol.16, pp.908-918, 2015.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N. Engl. J. Med, vol.378, pp.158-168, 2018.

J. Naidoo, Pneumonitis in Patients Treated With Anti-Programmed Death

, Programmed Death Ligand 1 Therapy, J. Clin. Oncol, vol.35, pp.709-717, 2017.

L. K. Collins, M. S. Chapman, J. B. Carter, and F. H. Samie, Cutaneous adverse effects of the immune checkpoint inhibitors, Curr. Probl. Cancer, vol.41, pp.125-128, 2017.

J. Naidoo, Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1, Cancer Immunol. Res, vol.4, pp.383-389, 2016.

J. C. Kao, Neurological Complications Associated With Anti-Programmed Death, vol.1

A. , , vol.74, pp.1216-1222, 2017.

H. Montaudié, J. Pradelli, T. Passeron, J. Lacour, and S. Leroy, Sarcoïdose pulmonaire induite par le nivolumab, Ann. Dermatol. Vénéréologie, vol.143, pp.359-360, 2016.

T. K. Eigentler, Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat. Rev, vol.45, pp.7-18, 2016.

S. Champiat, Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann. Oncol, vol.27, pp.559-574, 2016.

M. Delaunay, Toxicité des inhibiteurs de points de contrôle immunitaires, Rev. Mal. Respir, vol.35, pp.1028-1038, 2018.

I. Puzanov, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunother. Cancer, vol.5, p.95, 2017.

J. B. Haanen, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.28, pp.119-142, 2017.

H. Davies, Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002.

G. V. Long, Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.667-673, 2018.

J. Charles, Mécanismes de résistance aux inhibiteurs de BRAF, Ann. Dermatol. Vénéréologie, vol.141, pp.671-681, 2014.

P. B. Chapman, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011.

P. A. Ascierto, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, vol.17, pp.1248-1260, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01407426

A. Hauschild, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, Lancet Lond. Engl, vol.380, pp.358-365, 2012.

G. V. Long, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.28, pp.1631-1639, 2017.

C. Robert, Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N. Engl. J. Med, 2019.

R. Dummer, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.19, pp.603-615, 2018.

R. Addeo, S. Zappavigna, A. Luce, S. Facchini, and M. Caraglia, Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC, Expert Opin. Drug Saf, vol.12, pp.729-740, 2013.

P. O. Lang, S. Govind, and R. Aspinall, NPG Neurol. -Psychiatr. -Gériatrie, vol.12, pp.171-181, 2012.

G. Berrut, L. Decker, C. Sunderkötter, H. Kalden, and T. A. Luger, Aging and the skin immune system, Gériatrie Psychol. Neuropsychiatr. Viellissement, vol.7, pp.1256-1262, 1997.

E. Zuelgaray, Caractérisation phénotypique des lymphocytes T résidents de la peau sénescente, Ann. Dermatol. Vénéréologie, vol.145, p.306, 2018.

G. Colonna-romano, B Cell Immunosenescence in the Elderly and in Centenarians, Rejuvenation Res, vol.11, pp.433-439, 2008.

A. Waterstrat and G. Van-zant, Effects of aging on hematopoietic stem and progenitor cells, Curr. Opin. Immunol, vol.21, pp.408-413, 2009.

A. Gruver, L. Hudson, and G. Sempowski, Immunosenescence of ageing, J. Pathol, vol.211, pp.144-156, 2007.

D. B. Palmer, The Effect of Age on Thymic Function, Front. Immunol, vol.4, 2013.

V. Appay, D. Sauce, and M. Prelog, The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals, Aging, vol.2, pp.78-81, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02455362

C. F. Fortin, P. P. Mcdonald, O. Lesur, and T. Fülöp, Aging and Neutrophils: There Is Still Much To Do, Rejuvenation Res, vol.11, pp.873-882, 2008.

A. Panda, Human innate immunosenescence: causes and consequences for immunity in old age, Trends Immunol, vol.30, pp.325-333, 2009.

C. F. Fortin, A. Larbi, G. Dupuis, O. Lesur, and T. Fülöp, GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals, Biogerontology, vol.8, pp.173-187, 2007.

Y. Jing, Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood, Hum. Immunol, vol.70, pp.777-784, 2009.

A. Panda, Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J. Immunol. Baltim. Md, vol.184, pp.2518-2527, 1950.

H. Bruunsgaard, K. Andersen-ranberg, B. Hjelmborg, B. K. Pedersen, and B. Jeune, Elevated levels of tumor necrosis factor alpha and mortality in centenarians, Am. J. Med, vol.115, pp.278-283, 2003.

L. Haynes and S. L. Swain, Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects, Semin. Immunol, vol.24, pp.350-355, 2012.

H. Tsukamoto, Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.18333-18338, 2009.

R. Gregg, The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age, Clin. Exp. Immunol, vol.140, pp.540-546, 2005.

J. E. Nagel, Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors, J. Clin. Invest, vol.81, pp.1096-1102, 1988.

L. Haynes and A. C. Maue, Effects of aging on T cell function, Curr. Opin. Immunol, vol.21, pp.414-417, 2009.

S. Ponnappan and U. Ponnappan, Aging and immune function: molecular mechanisms to interventions, Antioxid. Redox Signal, vol.14, pp.1551-1585, 2011.

J. Dwilewicz-trojaczek, Chronic lymphatic leukemia from B CD5+ cells: characteristics, clinical and laboratory features, and immunophenotyping

, Pol. Tyg. Lek. Wars. Pol, vol.50, pp.12-14, 1960.

Y. Lin, Changes in blood lymphocyte numbers with age in vivo and their association with the levels of cytokines/cytokine receptors, Immun. Ageing A, vol.13, p.24, 2016.

H. Li, W. Liu, and J. Xie, Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis, Arch. Gerontol. Geriatr, vol.73, pp.257-262, 2017.

E. T. Roberts, M. N. Haan, J. B. Dowd, and A. E. Aiello, Cytomegalovirus Antibody Levels, Inflammation, and Mortality Among Elderly Latinos Over 9 Years of Follow-up, Am. J. Epidemiol, vol.172, pp.363-371, 2010.

A. M. Simanek, Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States, PloS One, vol.6, p.16103, 2011.

H. W. Virgin, E. J. Wherry, and R. Ahmed, Redefining Chronic Viral Infection, Cell, vol.138, pp.30-50, 2009.

S. R. Hadrup, Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly, J. Immunol. Baltim. Md, vol.176, pp.2645-2653, 1950.

C. M. Weyand, J. C. Brandes, D. Schmidt, J. W. Fulbright, and J. J. Goronzy, Functional properties of CD4+ CD28-T cells in the aging immune system, Mech. Ageing Dev, vol.102, pp.131-147, 1998.

M. G. Dorrington and D. M. Bowdish, Immunosenescence and novel vaccination strategies for the elderly, Front. Immunol, vol.4, p.171, 2013.

A. Daste, Immune checkpoint inhibitors and elderly people: A review, Eur. J. Cancer, vol.82, pp.155-166, 2017.

Y. Youm, Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging, Cell Metab, vol.18, pp.519-532, 2013.

C. Falci, Immune senescence and cancer in elderly patients: results from an exploratory study, Exp. Gerontol, vol.48, pp.1436-1442, 2013.

A. Grolleau-julius, E. K. Harning, L. M. Abernathy, and R. L. Yung, Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity, Cancer Res, vol.68, pp.6341-6349, 2008.

C. Matheï, B. Vaes, P. Wallemacq, and J. Degryse, Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort, J. Am. Geriatr. Soc, vol.59, pp.2201-2208, 2011.

G. Pawelec, Does patient age influence anti-cancer immunity?, Semin. Immunopathol, 2018.

A. Martens, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01409624

K. Poropatich, J. Fontanarosa, S. Samant, J. A. Sosman, and B. Zhang, Cancer Immunotherapies: Are They as Effective in the Elderly?, Drugs Aging, vol.34, pp.567-581, 2017.

G. Pawelec, Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?, Clin. Cancer Res, vol.24, pp.5193-5194, 2018.

C. H. Kugel, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.24, pp.5347-5356, 2018.

Z. Vadasz, T. Haj, A. Kessel, and E. Toubi, Age-related autoimmunity, BMC Med, vol.11, 2013.

J. H. Lewis, Participation of patients 65 years of age or older in cancer clinical trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.21, pp.1383-1389, 2003.

A. S. Betof, Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, The Oncologist, vol.22, pp.963-971, 2017.

C. Sileni and V. , Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J. Exp. Clin. Cancer Res, vol.33, 2014.

V. Leroy, Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma, Cancer Immunol. Immunother, 2019.

M. Freeman and J. Weber, Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma, J. Immunother. Cancer, vol.3, 2015.

R. Rai, Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann. Oncol, vol.27, 2016.

T. Ibrahim, C. Mateus, M. Baz, and C. Robert, Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study, Cancer Immunol. Immunother, vol.67, pp.1571-1578, 2018.

G. Ben-betzalel, Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients, Eur. J. Cancer, vol.108, pp.61-68, 2019.

R. L. Maher, J. Hanlon, and E. R. Hajjar, Clinical consequences of polypharmacy in elderly, Expert Opin. Drug Saf, vol.13, pp.57-65, 2014.

C. Helissey, C. Vicier, and S. Champiat, The development of immunotherapy in older adults: New treatments, new toxicities?, J. Geriatr. Oncol, vol.7, pp.325-333, 2016.

M. N. Bouchlaka and W. J. Murphy, Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models, Oncoimmunology, vol.2, p.27186, 2013.

S. Bhandari, A. S. Gill, C. A. Perez, and D. Jain, Management of immunotherapy toxicities in older adults, Semin. Oncol, vol.45, pp.226-231, 2018.

W. S. Kendal, Dying with cancer: The influence of age, comorbidity, and cancer site, Cancer, vol.112, pp.1354-1362, 2008.

C. F. Friedman and J. D. Wolchok, Checkpoint inhibition and melanoma: Considerations in treating the older adult, J. Geriatr. Oncol, vol.8, pp.237-241, 2017.

A. N. Dubovsky, S. Arvikar, T. A. Stern, and L. Axelrod, The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited, Psychosomatics, vol.53, pp.103-115, 2012.

J. R. Brahmer, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.36, pp.1714-1768, 2018.

L. Fardet, I. Petersen, and I. Nazareth, Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study, PLOS Med, vol.13, p.1002024, 2016.

, Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.153-159, 1993.

K. A. Malkhasyan, Y. Zakharia, and M. Milhem, Quality-of-life outcomes in patients with advanced melanoma: A review of the literature, Pigment Cell Melanoma Res, vol.30, pp.511-520, 2017.

M. A. Sprangers, A. Cull, K. Bjordal, M. Groenvold, and N. K. Aaronson, The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules, EORTC Study Group on Quality of Life. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil, vol.2, pp.287-295, 1993.

N. K. Aaronson, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993.

J. S. Weber, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, vol.16, pp.375-384, 2015.

D. Schadendorf, Health-related quality of life results from the phase III CheckMate 067 study, Eur. J. Cancer, vol.82, pp.80-91, 2017.

L. Balducci and M. Extermann, Management of cancer in the older person: a practical approach, The Oncologist, vol.5, pp.224-237, 2000.

P. Soubeyran, Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS One, vol.9, p.115060, 2014.

C. Martinez-tapia, Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer, Eur. J. Cancer, vol.83, pp.211-219, 2017.

R. Mccorkle, A specialized home care intervention improves survival among older postsurgical cancer patients, J. Am. Geriatr. Soc, vol.48, pp.1707-1713, 2000.

M. Extermann, A comprehensive geriatric intervention detects multiple problems in older breast cancer patients, Crit. Rev. Oncol. Hematol, vol.49, pp.69-75, 2004.

V. Girre, Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?, J. Gerontol. A. Biol. Sci. Med. Sci, vol.63, pp.724-730, 2008.

P. Caillet, Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, J. Clin. Oncol, vol.29, pp.3636-3642, 2011.

S. Novello, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann. Oncol, vol.27, pp.1-27, 2016.

F. Grossi, Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme, Eur. J. Cancer, vol.100, pp.126-134, 2018.

Y. Wu, Q. Ju, B. Qian, F. Zhang, and H. Shi, The effectiveness of PD-1 inhibitors in nonsmall cell lung cancer (NSCLC) patients of different ages, Oncotarget, vol.9, 2018.

R. Elias, J. Morales, and C. Presley, Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults, Curr. Oncol. Rep, vol.19, 2017.

N. Malats and F. X. Real, Epidemiology of bladder cancer, Hematol. Oncol. Clin. North Am, vol.29, pp.177-189, 2015.

C. Kandoth, Mutational landscape and significance across 12 major cancer types, Nature, vol.502, pp.333-339, 2013.

D. Stenehjem, D. Tran, M. Nkrumah, and S. Gupta, PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer, OncoTargets Ther, vol.11, pp.5973-5989, 2018.

J. Bellmunt, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017.

M. D. Galsky, A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy, Lancet Oncol, vol.12, pp.211-214, 2011.

A. V. Balar, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, singlearm, phase 2 study, Lancet Oncol, vol.18, pp.1483-1492, 2017.

P. Sharma, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-322, 2017.

A. M. Menzies, Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Ann. Oncol, vol.443, 2016.

A. Ackerman, Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors: Sequencing of Melanoma Therapies, Cancer, vol.120, pp.1695-1701, 2014.

M. Amini-adle, Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma, BMC Cancer, vol.18, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01911405

Q. Ma, Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data, BMC Cancer, vol.18, 2018.

J. L. Mcquade, Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis, Lancet Oncol, vol.19, pp.310-322, 2018.

M. B. Atkins and J. Larkin, Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives, JNCI J. Natl. Cancer Inst, vol.108, 2016.

M. S. Pelster and R. N. Amaria, Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials, Ther. Adv. Med. Oncol, vol.11, p.175883591983082, 2019.

B. Pulluri, A. Kumar, M. Shaheen, J. Jeter, and S. Sundararajan, Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance, Pharmacol. Res, vol.123, pp.95-102, 2017.

A. Ribas, F. S. Hodi, M. Callahan, C. Konto, and J. Wolchok, Hepatotoxicity with Combination of Vemurafenib and Ipilimumab, N. Engl. J. Med, vol.368, pp.1365-1366, 2013.

A. Ribas, Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J. Clin. Oncol, vol.33, pp.3003-3003, 2015.

R. J. Sullivan, Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity, J. Clin. Oncol, vol.35, pp.3063-3063, 2017.

P. A. Ascierto, 1244OKEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma, Ann. Oncol, vol.29, 2018.

H. A. Tawbi and -. , Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM), J. Clin. Oncol, vol.36, pp.9560-9560, 2018.

R. Dummer, Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma, J. Clin. Oncol, vol.36, pp.189-189, 2018.

P. A. Ascierto, Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program, Cancer Invest, vol.32, pp.144-149, 2014.

H. A. Tawbi, Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain, N. Engl. J. Med, vol.379, pp.722-730, 2018.

G. V. Long, Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort, J. Clin. Oncol, vol.34, pp.9506-9506, 2016.

D. Schadendorf, Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, pp.3807-3814, 2017.

M. H. Pollack, Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma, Ann. Oncol, vol.29, pp.250-255, 2018.

J. Fernandes, Hospitalisation costs of metastatic melanoma in France; the MELISSA study, MELanoma In hoSpital coSts Assessment). BMC Health Serv. Res, vol.17, 2017.

S. R. Ghate, Z. Li, J. Tang, and A. R. Nakasato, Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly, Am. Health Drug Benefits, vol.11, pp.334-343, 2018.